Released : September 10, 2020 07:00 RNS Number : 5403Y MaxCyte, Inc. 10 September 2020 MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference GAITHERSBURG, MD , 10 September 2020 - MaxCyte, Inc.
Released : September 09, 2020 07:00 RNS Number : 3947Y MaxCyte, Inc. 09 September 2020 MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer - Murphy brings a wealth of life sciences capital markets
Released : September 02, 2020 14:57 RNS Number : 8572X MaxCyte, Inc. 02 September 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : September 02, 2020 07:00 RNS Number : 7362X MaxCyte, Inc. 02 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 2 September 2020 - MaxCyte, Inc.
Released : August 18, 2020 07:00 RNS Number : 3824W MaxCyte, Inc. 18 August 2020 CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 · New parallel cohort will broaden evaluation of MCY-M11 in patients through
Released : August 14, 2020 07:00 RNS Number : 1154W MaxCyte, Inc. 14 August 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : July 16, 2020 18:04 RNS Number : 2766T MaxCyte, Inc. 16 July 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Gaithersburg, Maryland - 16 July 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : July 15, 2020 07:00 RNS Number : 0040T MaxCyte, Inc. 15 July 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · First-half revenues at $10.9m delivering growth of 30% year-on-year · Launch of expanded new ExPERT ™ range of disposables to broaden
Released : July 08, 2020 07:00 RNS Number : 3179S MaxCyte, Inc. 08 July 2020 FOR IMMEDIATE RELEASE APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401 APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based
Released : July 01, 2020 07:00 RNS Number : 5842R MaxCyte, Inc. 01 July 2020 SCHEDULE 6 AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan c.
